Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash & Equivalents (2016 - 2026)

Organogenesis Holdings has reported Cash & Equivalents over the past 10 years, most recently at $93.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 30.9% year-over-year to $93.7 million; the TTM value through Dec 2025 reached $93.7 million, down 30.9%, while the annual FY2025 figure was $93.7 million, 30.9% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $93.7 million at Organogenesis Holdings, up from $63.7 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $135.6 million in Q4 2024 and troughed at $63.7 million in Q3 2025.
  • A 5-year average of $98.4 million and a median of $98.2 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 35.0% in 2021 and later tumbled 32.43% in 2025.
  • Year by year, Cash & Equivalents stood at $113.9 million in 2021, then dropped by 10.05% to $102.5 million in 2022, then increased by 1.33% to $103.8 million in 2023, then surged by 30.56% to $135.6 million in 2024, then tumbled by 30.9% to $93.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ORGO at $93.7 million in Q4 2025, $63.7 million in Q3 2025, and $73.1 million in Q2 2025.